RNA Interference (RNAi) Drug Delivery Market Outlook
Ribonucleic acid interference (RNAi) is the biological process through which RNA molecules induce sequence-specific inhibition of target gene expression. It is considered a precise approach for gene silencing and holds remarkable potential for treating several pathological conditions, such as viral infections, cardiovascular diseases (CVDs), and cancer.
The global RNA interference (RNAi) drug delivery market reached a value of US$ 54.74 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 184.98 Billion by 2027, exhibiting at a CAGR of 22.5% during 2022-2027.
RNAi drug delivery is administered through intra-dermal, intravenous, and intraperitoneal injections and topical delivery methods. It involves nucleic acid, nanoparticle, pulmonary, and aptamer drug delivery technologies. RNAi is widely applied in drug development and gene silencing due to its high level of specificity, ease of synthesis, and minor side effects. The drug delivery is also used to treat chronic metabolic, cardiovascular, neurological, and ophthalmological disorders.
Request for a PDF sample of this report: https://www.imarcgroup.com/rna-interference-drug-delivery-market
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
RNA Interference (RNAi) Drug Delivery Market Trends:
The increasing geriatric population and the rising prevalence of genetic and chronic medical ailments are some of the key factors primarily accelerating the market growth. Additionally, the recent COVID-19 outbreak has significantly surged the demand for RNAi drug delivery technologies that can inhibit the expression of viral antigens, which is creating a positive outlook for the market.
Moreover, the development of innovative bio-vectors and synthetic delivery carriers and rising demand for personalized medicines are bolstering the market growth. Other factors, such as burgeoning investments in research and development (RD) activities and the rapidly expanding healthcare infrastructure, are positively contributing to the market.
Buy This Report Now: https://www.imarcgroup.com/checkout?id=2758method=1
In this report you will get detailed analysis of the market, growth analysis graphs, historical period analysis, forecast period analysis, major market segmentation, top leading key players of the market, table of content, list of figures, and list of tables.
Competitive Landscape with Key Players:
The report has also analysed the competitive landscape of the market with some of the key players.
- Alnylam Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- CureVac AG
- Dicerna Pharmaceuticals Inc.
- Gradalis Inc.
- Ionis Pharmaceuticals Inc
- Merck Co. Inc.
- Moderna Inc.
- Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
- Silence Therapeutics Plc
- Sirnaomics Inc.
Key Market Segmentation:
The report has categorized the market based on application and technology.
Breakup by Application:
- Infectious Disease
- Cardiology
- Oncology
- Neurology
- Ophthalmology
- Urology
- Metabolic Disorders
- Others
Breakup by Technology:
- Nanoparticle Drug Delivery
- Pulmonary Drug Delivery
- Nucleic Acid Drug Delivery
- Aptamer Drug Delivery
Breakup by Region:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, South Africa, Others)
Ask Analyst for Customization and Explore full report with TOC List of Figures: https://www.imarcgroup.com/request?type=reportid=2758flag=C
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022-2027)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
Related Reports by IMARC Group:
Latin America Generic Drug Market: https://www.imarcgroup.com/latin-america-generic-drug-market
North Africa Generic Drug Market: https://www.imarcgroup.com/north-africa-generic-drug-market
West Africa Generic Drug Market: https://www.imarcgroup.com/west-africa-generic-drug-market
East Africa Generic Drug Market: https://www.imarcgroup.com/east-africa-generic-drug-market
Europe Generic Drug Market: https://www.imarcgroup.com/europe-generic-drug-market
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas: - +1 631 791 1145 | Africa and Europe: - +44-702-409-7331 | Asia: +91-120-433-0800
